Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)
Launched by CENTRE HOSPITALIER INTERCOMMUNAL CRETEIL ·
Trial Information
Current as of September 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a fixed, low dose of a medicine called follitropin delta (brand name Rekovelle) to help stimulate the ovaries in women undergoing intrauterine insemination (IUI), a fertility treatment where sperm is placed directly into the uterus to help achieve pregnancy. The goal is to see if this specific dose can encourage the growth of two healthy follicles (the sacs in the ovaries that release eggs) to increase the chances of pregnancy while lowering the risk of having twins or more, which can happen with fertility treatments.
Women who have regular menstrual cycles and are interested in IUI for infertility may be eligible to participate. During the study, participants will receive the same fixed dose of Rekovelle to stimulate their ovaries before insemination. This approach aims to make treatment more predictable, comfortable, and efficient, potentially helping women get pregnant faster. The trial is currently not yet recruiting, and it focuses on female participants within a wide age range.
Gender
FEMALE
Eligibility criteria
About Centre Hospitalier Intercommunal Creteil
Centre Hospitalier Intercommunal Créteil (CHIC) is a leading healthcare institution in the Val-de-Marne department of France, dedicated to delivering high-quality medical care and advancing clinical research. As a prominent clinical trial sponsor, CHIC collaborates with healthcare professionals and academic institutions to facilitate innovative research initiatives aimed at improving patient outcomes. The center is committed to adhering to rigorous ethical standards and regulatory guidelines, ensuring the safety and efficacy of interventions tested within its clinical trials. CHIC’s multidisciplinary approach fosters an environment of collaboration and excellence, positioning it as a key player in the advancement of medical knowledge and therapeutic options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Nicolas Chevalier
Principal Investigator
Centre AMP Saint Roch
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported